Valuation: Pulmatrix, Inc.

Market Cap 6.17M 5.41M 5M 4.6M 8.68M 595M 8.82M 59.8M 23.44M 291M 23.18M 22.67M 1B P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 2.08M 1.83M 1.69M 1.55M 2.93M 201M 2.98M 20.19M 7.92M 98.35M 7.83M 7.66M 339M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 -
1 day-2.96%
1 week+0.59%
Current month-1.18%
1 month+9.08%
3 months+24.90%
6 months-37.08%
Current year-24.67%
1 week 1.56
Extreme 1.557
1.69
1 month 1.41
Extreme 1.4101
1.88
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
6.3
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
20.8
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 20/07/2024
Director TitleAgeSince
Director/Board Member 58 01/11/2019
Director/Board Member 57 23/06/2020
Director/Board Member 55 01/10/2020
Date Insider Type Main position Quantity % Market Cap.
1/26/23 A Free

Director

1,700 0.0467%
1/26/23 A Free

Director

1,700 0.0467%
1/26/23 A Free

Chief Technology Officer

11,400 0.3133%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+0.59%-72.32%-34.63% 6.17M
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-0.67%-0.62%+5.53%+409.46% 23.48B
+11.37%+2.20%-15.48%-14.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-2.66%+0.36%+27.07%+183.04% 14.06B
Average +0.84%-0.25%+30.61%+159.88% 23.36B
Weighted average by Cap. +1.70%-0.73%+41.79%+141.12%

Financials

2024 2025
Net sales 7.81M 6.84M 6.32M 5.82M 10.97M 753M 11.15M 75.62M 29.64M 368M 29.31M 28.67M 1.27B -
Net income -9.56M -8.38M -7.74M -7.12M -13.44M -922M -13.66M -92.6M -36.3M -451M -35.89M -35.11M -1.55B -5.16M -4.52M -4.18M -3.85M -7.26M -498M -7.37M -50.01M -19.6M -244M -19.38M -18.96M -839M
Net Debt -9.52M -8.35M -7.71M -7.09M -13.39M -918M -13.6M -92.24M -36.16M -449M -35.75M -34.97M -1.55B -4.09M -3.58M -3.31M -3.05M -5.75M -394M -5.84M -39.6M -15.52M -193M -15.35M -15.02M -665M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
20/07/26 $1.680 -0.60% 12,521
17/07/26 $1.690 +4.97% 20,753
16/07/26 $1.610 +2.55% 14,612
15/07/26 $1.570 -3.09% 11,382
14/07/26 $1.620 -2.99% 25,804
  1. Stock Market
  2. Stocks
  3. PULM Stock